IRIDEX Corporation (IRIX) - Net Assets

Latest as of March 2026: $4.92 Million USD

Based on the latest financial reports, IRIDEX Corporation (IRIX) has net assets worth $4.92 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($29.15 Million) and total liabilities ($24.23 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check IRIDEX Corporation tangible equity quality to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets $4.92 Million
% of Total Assets 16.88%
Annual Growth Rate 0.15%
5-Year Change -78.87%
10-Year Change -87.43%
Growth Volatility 72.81

IRIDEX Corporation - Net Assets Trend (1995–2025)

This chart illustrates how IRIDEX Corporation's net assets have evolved over time, based on quarterly financial data. See how many days can IRIDEX Corporation fund operations to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for IRIDEX Corporation (1995–2025)

The table below shows the annual net assets of IRIDEX Corporation from 1995 to 2025. For live valuation and market cap data, see IRIDEX Corporation (IRIX) market capitalisation.

Year Net Assets Change
2025-12-31 $4.92 Million +134.72%
2024-12-31 $2.10 Million -77.98%
2023-12-31 $9.52 Million -44.74%
2022-12-31 $17.23 Million -26.04%
2021-12-31 $23.30 Million +34.16%
2020-12-31 $17.37 Million -23.51%
2019-12-31 $22.70 Million -24.22%
2018-12-31 $29.96 Million -1.84%
2017-12-31 $30.52 Million -22.06%
2016-12-31 $39.16 Million +16.24%
2015-12-31 $33.69 Million -0.14%
2014-12-31 $33.74 Million +30.49%
2013-12-31 $25.85 Million +18.03%
2012-12-31 $21.91 Million -2.32%
2011-12-31 $22.43 Million +15.44%
2010-12-31 $19.43 Million +29.29%
2009-12-31 $15.03 Million +27.92%
2008-12-31 $11.75 Million -37.55%
2007-12-31 $18.81 Million -41.51%
2006-12-31 $32.16 Million -6.84%
2005-12-31 $34.52 Million +8.60%
2004-12-31 $31.78 Million +3.08%
2003-12-31 $30.83 Million +2.11%
2002-12-31 $30.20 Million +1.22%
2001-12-31 $29.83 Million -2.19%
2000-12-31 $30.50 Million +10.89%
1999-12-31 $27.50 Million +6.19%
1998-12-31 $25.90 Million +8.37%
1997-12-31 $23.90 Million +11.16%
1996-12-31 $21.50 Million +357.45%
1995-12-31 $4.70 Million --

Equity Component Analysis

This analysis shows how different components contribute to IRIDEX Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 9164600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock $174.00K 3.54%
Other Comprehensive Income $-14.00K -0.28%
Other Components $97.21 Million 1974.97%
Total Equity $4.92 Million 100.00%

IRIDEX Corporation Competitors by Market Cap

The table below lists competitors of IRIDEX Corporation ranked by their market capitalization.

Company Market Cap
bet-at-home.com AG
F:ACX
 $17.94 Million
Volt Power Group Ltd
AU:VPR
 $17.95 Million
Drillcon AB
ST:DRIL
 $17.95 Million
O.C.C. Public Company Limited
BK:OCC
 $17.95 Million
Eagle Plains Resources Ltd.
V:EPL
 $17.92 Million
Benalec Holdings Bhd
KLSE:5190
 $17.91 Million
FACILITIES BY ADF LS-01
F:ZC8
 $17.90 Million
Barrel Co. Ltd
KQ:267790
 $17.90 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in IRIDEX Corporation's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 2,097,000 to 4,922,000, a change of 2,825,000 (134.7%).
  • Net loss of 4,437,000 reduced equity.
  • New share issuances of 10,000,000 increased equity.
  • Other comprehensive income decreased equity by 65,000.
  • Other factors decreased equity by 2,673,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income $-4.44 Million -90.15%
Share Issuances $10.00 Million +203.17%
Other Comprehensive Income $-65.00K -1.32%
Other Changes $-2.67 Million -54.31%
Total Change $- 134.72%

Book Value vs Market Value Analysis

This analysis compares IRIDEX Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 4.09x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 1.07x to 4.09x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1995-12-31 $1.10 $1.17 x
1996-12-31 $3.44 $1.17 x
1997-12-31 $3.54 $1.17 x
1998-12-31 $3.83 $1.17 x
1999-12-31 $4.02 $1.17 x
2000-12-31 $4.19 $1.17 x
2001-12-31 $4.42 $1.17 x
2002-12-31 $4.36 $1.17 x
2003-12-31 $4.16 $1.17 x
2004-12-31 $4.41 $1.17 x
2005-12-31 $4.38 $1.17 x
2006-12-31 $4.17 $1.17 x
2007-12-31 $2.27 $1.17 x
2008-12-31 $1.33 $1.17 x
2009-12-31 $1.68 $1.17 x
2010-12-31 $1.92 $1.17 x
2011-12-31 $2.19 $1.17 x
2012-12-31 $2.45 $1.17 x
2013-12-31 $2.56 $1.17 x
2014-12-31 $3.26 $1.17 x
2015-12-31 $3.33 $1.17 x
2016-12-31 $3.85 $1.17 x
2017-12-31 $2.64 $1.17 x
2018-12-31 $2.46 $1.17 x
2019-12-31 $1.66 $1.17 x
2020-12-31 $1.25 $1.17 x
2021-12-31 $1.51 $1.17 x
2022-12-31 $1.08 $1.17 x
2023-12-31 $0.59 $1.17 x
2024-12-31 $0.13 $1.17 x
2025-12-31 $0.29 $1.17 x

Capital Efficiency Dashboard

This dashboard shows how efficiently IRIDEX Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -90.15%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -8.42%
  • • Asset Turnover: 1.81x
  • • Equity Multiplier: 5.92x
  • Recent ROE (-90.15%) is below the historical average (-29.80%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1995 21.28% 11.36% 1.38x 1.36x $530.00K
1996 4.65% 8.06% 0.52x 1.10x $-1.15 Million
1997 8.79% 11.60% 0.68x 1.12x $-290.00K
1998 6.56% 7.20% 0.83x 1.10x $-890.00K
1999 5.88% 6.05% 0.82x 1.19x $-1.13 Million
2000 7.92% 7.23% 0.95x 1.15x $-634.00K
2001 -4.27% -4.67% 0.81x 1.13x $-4.26 Million
2002 0.50% 0.49% 0.89x 1.13x $-2.87 Million
2003 1.20% 1.17% 0.88x 1.16x $-2.71 Million
2004 -1.26% -1.23% 0.84x 1.23x $-3.58 Million
2005 4.84% 4.51% 0.90x 1.19x $-1.78 Million
2006 -17.89% -16.02% 0.89x 1.25x $-8.97 Million
2007 -118.41% -40.11% 1.19x 2.48x $-24.15 Million
2008 -62.74% -15.19% 1.72x 2.40x $-8.54 Million
2009 17.20% 5.98% 1.53x 1.88x $1.08 Million
2010 15.68% 6.97% 1.50x 1.50x $1.10 Million
2011 11.64% 7.87% 1.03x 1.43x $367.40K
2012 6.56% 4.25% 1.17x 1.32x $-752.50K
2013 8.63% 5.83% 1.14x 1.30x $-354.40K
2014 29.75% 23.45% 1.02x 1.24x $6.66 Million
2015 1.41% 1.14% 1.00x 1.24x $-2.89 Million
2016 -29.91% -25.38% 0.96x 1.23x $-15.63 Million
2017 -42.16% -30.94% 1.00x 1.36x $-15.92 Million
2018 -42.77% -30.08% 1.02x 1.39x $-15.81 Million
2019 -38.82% -20.28% 1.25x 1.53x $-11.08 Million
2020 -36.44% -17.41% 1.30x 1.61x $-8.07 Million
2021 -22.43% -9.69% 1.11x 2.09x $-7.55 Million
2022 -43.80% -13.25% 1.35x 2.45x $-9.27 Million
2023 -100.50% -18.45% 1.51x 3.62x $-10.52 Million
2024 -424.89% -18.31% 1.67x 13.89x $-9.12 Million
2025 -90.15% -8.42% 1.81x 5.92x $-4.93 Million

Industry Comparison

This section compares IRIDEX Corporation's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $1,818,520,110
  • Average return on equity (ROE) among peers: -48.87%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
IRIDEX Corporation (IRIX) $4.92 Million 21.28% 4.92x $17.92 Million
Abbott Laboratories (ABT) $17.78 Billion 20.28% 1.23x $153.89 Billion
Adagio Medical Holdings, Inc Common Stock (ADGM) $19.91 Million -270.00% 1.43x $15.55 Million
Aethlon Medical Inc (AEMD) $-5.98 Million 0.00% 0.00x $2.51 Million
Acutus Medical Inc (AFIB) $126.58 Million -80.56% 0.52x $903.35K
Adapthealth Corp (AHCO) $280.85 Million -57.55% 5.46x $1.29 Billion
20/20 Biolabs, Inc. Common Stock (AIDX) $6.89 Million 30.07% 0.49x $6.67 Million
Allurion Technologies, Inc. (ALUR) $-70.49 Million 0.00% 0.00x $7.70 Million
Autonomix Medical, Inc. Common Stock (AMIX) $8.10 Million -140.88% 0.21x $4.44 Million
Artivion Inc (AORT) $17.90 Million 7.26% 0.20x $1.03 Billion
Apyx Medical Inc (APYX) $22.89 Million 2.69% 0.23x $176.29 Million

About IRIDEX Corporation

NASDAQ:IRIX USA Medical Devices
Market Cap
$20.35 Million
Market Cap Rank
#25491 Global
#5327 in USA
Share Price
$1.17
Change (1 day)
-1.68%
52-Week Range
$0.88 - $1.56
All Time High
$16.39
Categories
Companies in USA Medical Devices
About

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and Oc… Read more